This site is intended for healthcare professionals outside the United States

CML 2021: How to manage treatment failure in CML

A patient-based approach

Meet the Expert: Session 3

Blast crisis, clonal evolution and stem cell transplantation

Wednesday 1st December 2021, 6-7pm (CET)

Our final Meet the Expert session will take a look at the role of clonal evolution in disease progression, treatment options if the blast phase is reached, and where stem cell transplantation should still be considered.

Prof. Jane F. Apperley, MD, FRCP, FRCPath, FMedSci

Imperial College Healthcare NHS Trust, London, England

Prof. Jane Apperley is the Chair of Haemato-Oncology at Hammersmith Hospital, London, and up until 2021, the Clinical Director for Clinical Haematology at the Imperial College Healthcare NHS Trust, London, and the Chair of the Centre of Haematology at the Imperial College, London. Prof. Apperley’s research interests include the biology and management of CML, including the use of tyrosine kinase inhibitors, and the effects of hematological diseases and their treatment on fertility, pregnancy and foetal outcomes. She has been a member of the European LeukemiaNet (ELN) CML Working Party since 2004 and has been involved with the ELN Consensus Guidelines since the first recommendations in 2006, initially as the ‘expert’ in stem cell transplantation. Prof. Apperley will lead the next version of the guidelines, with a predicted publication date of 2023. She has also been a member of the UK National Cancer Research Institute CML study group for >20 years, and played a key role in the development of the current British Committee For Standards In Haematology guidelines. Prof. Apperley is on the Board of Directors of the iCMLf and in 2021 became the Chair of the EHA Scientific Working Group in CML.

Faculty

  • Prof. Dr. Thomas Ernst
  • Prof. Susanne Saußele

Prof. Dr. Thomas Ernst, MD

Universitätsklinikum Jena, Jena, Germany

 

Prof. Thomas Ernst is coordinator of the University Tumor Center (UTC) and consultant of the Department of Hematology and Medical Oncology at the Jena University Hospital, Jena, Germany.

He obtained his medical degree from the University of Heidelberg in 2004, Germany. After 3 years in Mannheim, Germany, in the working group of Prof. Hehlmann, he spent another 3 years as a postdoctoral researcher at the Wessex Regional Genetics Laboratory (Prof Nick Cross) in Salisbury, UK. He then joined the Department of Hematology and Oncology (Prof Hochhaus) at the Jena University Hospital, Germany, where he became a specialist in internal medicine and hematology/medical oncology. Since 2015 he is senior consultant of the department and leads the CML research and diagnostic group. In 2020, he was appointed as an Associate Professor.

Prof. Susanne Saußele, MD

III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, Mannheim, Germany

 

Prof. Susanne Saußele is Head of the CML Excellence Center and chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, both in Mannheim, Germany. She studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. In 2017, she was appointed as Professor of the University of Heidelberg.

Prof. Saußele is also a project leader in EUTOS (European Treatment and Outcome study of CML) and is a member of the E-MPN (European Network for MPN), ELN CML Working Party and Scientific Program Committee of EHA.

Register your interest

By registering to attend you will receive:

Funding

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.